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Hairy cell leukemia is a rare indolent lymphoproliferative
malignancy characterized by splenomegaly and pancytopenia.
Patients are prone to acquire life-threatening infections and can
develop mycobacterial diseases.1 Traditional tools for tubercu-
losis diagnosis rely on the identification of mycobacteria
through microscopy and culture. These methods have low
sensitivity and so cannot usefully rule out a diagnosis of
tuberculosis where this is suspected. Moreover, mycobacterial
culture can take several weeks, often delaying diagnosis and
initiation of therapy. As a result, a significant proportion of
tuberculosis patients are diagnosed only at autopsy. This
diagnostic delay, and its adverse consequences, are even greater
in immunosuppressed patients in whom the clinical presenta-
tion is frequently nonspecific and the progression of tuberculosis
is more rapid.
The tuberculin skin test (TST) confirms infection and not
active disease, but in low burden countries (where the
prevalence of latent tuberculosis infection in the general
population is low), a positive TST result can help in the decision
to start treatment while mycobacterial culture results are
awaited, or support a clinical diagnosis of tuberculosis when
bacteriological confirmation is lacking. Conversely, a negative
result might, in theory, help to rule out a diagnosis of
tuberculosis. However, the TST is of little help in immunosup-
pressed patients, such as those with hematological malignan-
cies, who often have falsely negative TST results.2 A test of
Mycobacterium tuberculosis infection with high diagnostic
sensitivity would therefore be useful in the evaluation of
immunosuppressed patients where tuberculosis is included in
the differential diagnosis. The ex vivo enzyme-linked immuno-
spot (ELISPOT) assay is a very sensitive method for detecting low
frequencies of antigen-specific interferon-g-producing T cells
direct from peripheral blood. Thus, it may provide a more
sensitive means of detecting M. tuberculosis-specific immune
responses than the TST, which measures cutaneous delayed-
type hypersensitivity to purified protein derivative (PPD). Two
M. tuberculosis gene products, early secretory antigen target-6
(ESAT-6) and culture filtrate protein-10 (CFP-10), are strong
targets of cellular immune response in tuberculosis patients and
contacts.3 Recently, the ELISPOT-RD1 assay for interferon-
g-producing T-cells specific for ESAT-6 or CFP-10 peptides, has
been demonstrated to be a rapid, highly sensitive and specific
diagnostic tool for the detection of M. tuberculosis infection,
including in immunosuppressed individuals.4–6 Here, we
describe how the ELISPOT-RD1 accelerated the diagnosis of
disseminated tuberculosis in a leukemic patient with persistent
fever and a negative TST.
A 68-year-old Caucasian woman presented with fatigue,
weight loss, night sweats and fever. Her medical history
revealed that her mother died of tuberculous osteomyelitis.
Physical examination showed splenomegaly, without peripheral
lymphadenopathy. The peripheral blood count showed hemo-
Figure 1 (a) Fever chart, showing the intermittent course of body
temperature, and the progressive slow down after starting of the anti-
TB treatment. (b) Pleural fluid staining (May–Grunwald–Giemsa,
130 ), showing a prevalence of neutrophils, with few lymphocytes,
mesothelial cells and rare red blood cells. No malignant cells are
present. (c) Bone marrow biopsy (Hematoxylin–Eosin staining, 100 )
with a 30% infiltration of HCL cells (significantly reduced, compared
to the 90% infiltration in the bone marrow biopsy before starting
interferon-a 2b therapy); two noncaseating granulomas are present.
Acid-fast staining was negative.
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globin 9.0 g/dl, white blood cells 2.2 109/l and platelet count
69 109/l. A bone marrow biopsy revealed 90% of cells
expressing CD20, CD25, CD11c and CD103, consistent with
a diagnosis of hairy cell leukemia. An abdominal computed
tomography (CT) scan confirmed the splenomegaly, with multi-
ple hypodense lesions. A chest radiogram was normal. There-
fore, the patient was treated with interferon-a2b, 2 106/m2 IU
three times a week. After 2 months, she was readmitted to the
hospital for persistent fever. Despite improvement in the blood
count, an abdominal CT scan showed the splenic lesions to be
unchanged. Chest CT scan revealed minimal bilateral pleural
effusions. At that time, interferon therapy was withdrawn. The
day after admission, samples from blood, urine, faeces and
pleural fluid were obtained for microbiologic examination. The
following day the patient underwent bronchoscopy with
bronchoalveolar lavage (BAL). TST was negative (induration
1 mm after 72 h, using 5 IU of PPD). At 1 week after admission,
despite step-wise usage of empirical antimicrobial treatment the
fever persisted and the patient’s condition worsened (Figure 1a).
All tests for mycobacterial, bacterial, fungal and viral pathogens
were negative. Similarly, microscopic examination for acid-fast
bacilli was negative. Pleural fluid microscopy yielded an
inflammatory effusion with a prevalence of neutrophils together
with a small number of macrophages, lymphocytes and
activated mesothelial cells (Figure 1b). Recognising the possi-
bility that the TST result in this immunosuppressed patient might
be falsely negative, we performed an ex vivo ELISPOT-RD1 test
on blood, as previously described.4
The ELISPOT-RD1 assay enumerated 38 spot forming cells
(SFC) per million peripheral blood mononuclear cells (PBMC) in
response to recombinant ESAT-6 in the blood sample. Although
slightly below the usual cutoff of 40 SFC per million PBMC, this
level of T-cells specific for ESAT-6 in this patient strongly
suggested M. tuberculosis infection. This is because T cells in
leukemic patients show phenotypic and functional abnormal-
ities,7 with low numbers of CD4þ /CD45ROþ memory T
cells,8 the main contributors to IFN-g production. Indeed, in our
patient, the overall number of peripheral blood T cells was
approximately one third of normal (13 vs 25–35% in normal
individuals). Thus, the fact that this ELISPOT-RD1 assay was
performed with about one third of the number of T cells usually
used justified the use of a lower threshold for a positive test
result. This was also reflected in the weak result obtained in the
positive control wells (Phytohemaglutinin: 140 SFC/million
PBMC), which usually have more than 500 SFC/million PBMC.
Therefore, the ELISPOT-RD1 response to ESAT-6 was interpreted
as indicative of tuberculosis infection and accelerated the
diagnosis, prompting the initiation of antituberculosis therapy.
After 4 weeks, the patient developed a large pleural effusion.
Although the cellular infiltrate was atypical (Figure 1b), an
ELISPOT-RD1 test on a sample of pleural fluid tested strongly
positive (ESAT-6: 192; CFP-10: 424 SFC/million PBMC). Bone
marrow histological examination showed reduction of leukemic
infiltration to 30% but revealed the presence of a noncaseating
granulomatous reaction (Figure 1c). Acid-fast staining was
negative. At 18 days after initiation of anti-TB therapy based
upon ELISPOT-RD1 results, a peripheral blood sample that
had been taken the day of admission grew a mycobacterial
species, which was subsequently identified 3 weeks later as
M. tuberculosis, thus confirming the diagnosis of disseminated
tuberculosis (Figure 2). This was the only microbiologic
evidence of tuberculosis, since culture of pleural fluid, BAL
and bone marrow were all negative. At 1 month after starting
anti-tuberculosis therapy the TST turned positive (10 mm) and
the ELISPOT-RD1 remained persistently positive both in blood
and in pleural fluid. After 2 months of anti-tuberculosis therapy,
the patient was apyrexial and CT scan showed the resolution of
the pleural effusions. Abdominal CT scan revealed the
disappearance of most and the reduction in size of the
remaining splenic lesions, indicating that the splenic abnorm-
alities were secondary to disseminated tuberculosis.
The ELISPOT-RD1 detected M. tuberculosis infection, and
enabled an early diagnosis of active tuberculosis in our
immunosuppressed TST-negative patient in the absence of any
other finding suggestive of active tuberculosis and before the
identification of mycobacteria in blood cultures. Therefore, the
ELISPOT-RD1 accelerated the correct diagnosis. Moreover, the
pleural fluid, with a cellular infiltrate that was atypical for
tuberculosis, also tested strongly positive by ELISPOT-RD1,
consistent with homing of ESAT-6-specific IFN-g-secreting T
cells to sites of active TB disease. The results reported here
represent the first application of the ELISPOT-RD1 to the timely
diagnosis of disseminated tuberculosis in patients with hemato-
logical malignancies. Large prospective studies are now
warranted to validate the clinical utility of ELISPOT-RD1 in
hematological patients with suspected tuberculosis in routine
practice.
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Figure 2 Timeline of the clinical events in the case reported. Dates are reported as weeks from first TST. ELISPOT-RD1 results are given as
frequency of ESAT-6-specific interferon-gamma-secreting T cells (spot forming cells (SFC)) per million peripheral mononuclear cells (PBMC). All
test conditions, including positive control (PHA), negative control (medium only) and test wells for recombinant ESAT-6 antigen and recombinant
CFP-10 antigen, were performed in duplicate wells containing 250 000 PBMC each, as previously described.4
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